Blue Ribbon Healthcare Limited 10165316 false 2024-11-01 2025-10-31 2025-10-31 The principal activity of the company is residential care activities for learning difficulties, mental health and substance abuse Digita Accounts Production Advanced 6.30.9574.0 true true true true 10165316 2024-11-01 2025-10-31 10165316 2025-10-31 10165316 bus:OrdinaryShareClass1 2025-10-31 10165316 bus:Consolidated 2025-10-31 10165316 core:AcceleratedTaxDepreciationDeferredTax 2025-10-31 10165316 core:ProvisionsDeferredTax 2025-10-31 10165316 core:RetainedEarningsAccumulatedLosses 2025-10-31 10165316 core:ShareCapital 2025-10-31 10165316 core:SharePremium 2025-10-31 10165316 core:HirePurchaseContracts core:CurrentFinancialInstruments 2025-10-31 10165316 core:HirePurchaseContracts core:Non-currentFinancialInstruments 2025-10-31 10165316 core:CurrentFinancialInstruments 2025-10-31 10165316 core:CurrentFinancialInstruments core:WithinOneYear 2025-10-31 10165316 core:Non-currentFinancialInstruments core:AfterOneYear 2025-10-31 10165316 core:BetweenTwoFiveYears 2025-10-31 10165316 core:MoreThanFiveYears 2025-10-31 10165316 core:WithinOneYear 2025-10-31 10165316 core:FurnitureFittingsToolsEquipment 2025-10-31 10165316 core:LandBuildings 2025-10-31 10165316 core:MotorVehicles 2025-10-31 10165316 bus:FRS102 2024-11-01 2025-10-31 10165316 bus:Audited 2024-11-01 2025-10-31 10165316 bus:FullAccounts 2024-11-01 2025-10-31 10165316 bus:RegisteredOffice 2024-11-01 2025-10-31 10165316 bus:Director1 2024-11-01 2025-10-31 10165316 bus:OrdinaryShareClass1 2024-11-01 2025-10-31 10165316 bus:Consolidated 2024-11-01 2025-10-31 10165316 bus:PrivateLimitedCompanyLtd 2024-11-01 2025-10-31 10165316 bus:Agent1 2024-11-01 2025-10-31 10165316 core:FinancialGuarantees 2024-11-01 2025-10-31 10165316 core:RetainedEarningsAccumulatedLosses 2024-11-01 2025-10-31 10165316 core:ShareCapital 2024-11-01 2025-10-31 10165316 core:SharePremium 2024-11-01 2025-10-31 10165316 core:LandBuildingsUnderOperatingLeases 2024-11-01 2025-10-31 10165316 core:OtherAssetsUnderOperatingLeases 2024-11-01 2025-10-31 10165316 core:FurnitureFittings 2024-11-01 2025-10-31 10165316 core:FurnitureFittingsToolsEquipment 2024-11-01 2025-10-31 10165316 core:LandBuildings 2024-11-01 2025-10-31 10165316 core:LeaseholdImprovements 2024-11-01 2025-10-31 10165316 core:MotorVehicles 2024-11-01 2025-10-31 10165316 core:OfficeEquipment 2024-11-01 2025-10-31 10165316 core:KeyManagementPersonnelCloseFamilyMembersEntitiesUnderKeyManagementPersonnelsControl 2024-11-01 2025-10-31 10165316 core:UKTax 2024-11-01 2025-10-31 10165316 countries:AllCountries 2024-11-01 2025-10-31 10165316 2024-10-31 10165316 core:RetainedEarningsAccumulatedLosses 2024-10-31 10165316 core:ShareCapital 2024-10-31 10165316 core:SharePremium 2024-10-31 10165316 core:FurnitureFittingsToolsEquipment 2024-10-31 10165316 core:LandBuildings 2024-10-31 10165316 core:MotorVehicles 2024-10-31 10165316 2023-11-01 2024-10-31 10165316 2024-10-31 10165316 bus:OrdinaryShareClass1 2024-10-31 10165316 core:AcceleratedTaxDepreciationDeferredTax 2024-10-31 10165316 core:ProvisionsDeferredTax 2024-10-31 10165316 core:RetainedEarningsAccumulatedLosses 2024-10-31 10165316 core:ShareCapital 2024-10-31 10165316 core:SharePremium 2024-10-31 10165316 core:HirePurchaseContracts core:CurrentFinancialInstruments 2024-10-31 10165316 core:HirePurchaseContracts core:Non-currentFinancialInstruments 2024-10-31 10165316 core:CurrentFinancialInstruments 2024-10-31 10165316 core:CurrentFinancialInstruments core:WithinOneYear 2024-10-31 10165316 core:Non-currentFinancialInstruments core:AfterOneYear 2024-10-31 10165316 core:BetweenTwoFiveYears 2024-10-31 10165316 core:MoreThanFiveYears 2024-10-31 10165316 core:WithinOneYear 2024-10-31 10165316 core:FurnitureFittingsToolsEquipment 2024-10-31 10165316 core:LandBuildings 2024-10-31 10165316 core:MotorVehicles 2024-10-31 10165316 core:RetainedEarningsAccumulatedLosses 2023-11-01 2024-10-31 10165316 core:ShareCapital 2023-11-01 2024-10-31 10165316 core:SharePremium 2023-11-01 2024-10-31 10165316 core:LandBuildingsUnderOperatingLeases 2023-11-01 2024-10-31 10165316 core:OtherAssetsUnderOperatingLeases 2023-11-01 2024-10-31 10165316 core:UKTax 2023-11-01 2024-10-31 10165316 2023-10-31 10165316 core:RetainedEarningsAccumulatedLosses 2023-10-31 10165316 core:ShareCapital 2023-10-31 10165316 core:SharePremium 2023-10-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 10165316 (England and Wales)

Blue Ribbon Healthcare Limited

Annual Report and Financial Statements

for the Year Ended 31 October 2025

 

Blue Ribbon Healthcare Limited

Contents

Company Information

1

Strategic Report

2

Director's Report

3 to 4

Statement of Director's Responsibilities

5

Independent Auditor's Report

6 to 9

Profit and Loss Account

10

Balance Sheet

11

Statement of Changes in Equity

12

Notes to the Financial Statements

13 to 22

 

Blue Ribbon Healthcare Limited

Company Information

Director

C L Smith

Registered office

Gemini House
Blakewater Road
Capricorn Park
Blackburn
BB1 5QR

Auditors

Hazlewoods LLP Windsor House
Bayshill Road
Cheltenham
GL50 3AT

 

Blue Ribbon Healthcare Limited

Strategic Report for the Year Ended 31 October 2025

The director presents her strategic report for the year ended 31 October 2025.

Principal activity

The principal activity of the company is residential care activities for learning difficulties, mental health and substance abuse

Fair review of the business

The results for the year, which are set out in the profit and loss, account show turnover of £17,039,738 (2024 - £14,178,999) and an operating profit of £1,485,951 (2024 - £1,512,767). At 31 October 2025, the company had net assets of £3,758,807 (2024 - £2,427,802). The directors consider the performance for the year and the financial position at the year end to be satisfactory.

Details of future developments, financial instruments, principal risks and uncertainties and key performance indicators are disclosed in the group financial statements of the company's ultimate parent company, Project Bluebell (Topco) Limited.

Approved by the director on 2 July 2026


C L Smith
Director

 

Blue Ribbon Healthcare Limited

Director's Report for the Year Ended 31 October 2025

The director presents her report and the financial statements for the year ended 31 October 2025.

Director of the company

The director who held office during the year was as follows:

C L Smith

Employment of disabled persons

The Group is committed to providing equal opportunities for all employees and applicants and maintains a zero-tolerance approach to discrimination throughout recruitment and employment practices. Policies and procedures are designed to promote fairness, dignity, and respect for every individual, regardless of background or personal circumstances.

We are dedicated to fostering an inclusive workplace culture where diversity is valued and colleagues are supported to achieve their full potential. Fairness and equality are embedded across all people management processes, including recruitment, training, career development, and progression opportunities.

The Group also recognises the importance of making reasonable adjustments where appropriate to support employees with disabilities and to ensure an accessible and inclusive working environment for all.

Employee involvement

We are committed to fostering an open and collaborative working environment where colleague feedback is actively encouraged and valued. Regular engagement initiatives, including our Group wide Ribbon Review surveys, provide employees with opportunities to share feedback on work related matters and contribute to the continuous improvement of the business.

In addition, we promote a monthly Workplace Experience Survey (Net Promoter Score) to measure colleague engagement, satisfaction, and advocacy across the Group. The insights gained from these surveys are reviewed carefully and used to inform actions that drive positive change, enhance the employee experience, and recognise areas of success across the organisation.

The Group remains focused on maintaining strong communication channels and ensuring colleagues feel heard, supported, and involved in the development of the business.

Financial instruments

Objectives and policies

The board constantly monitors the company's trading results and revise projections as appropriate to ensure that the company can meet its future obligations as they fall due.

Price risk, credit risk, liquidity risk and cash flow risk

Blue Ribbon’s offering is in the high acuity care market and hospital discharge and risks to pricing are limited.

Credit risk consists primarily of cash and trade receivables. Cash is deposited with major financial institutions and trade receivables risk is minimal given revenue is derived from public entities.

The Group finances its operations through cash generated from operations and external funding facilities.

Liquidity risk is managed through the preparation of annual, quarterly and monthly cash flows that include known cash commitments.

The Group has sufficient cash from operations and available facilities to fund these commitments.

Future developments and strategy

Blue Ribbon will continue to focus on delivering outstanding care to existing and new Service Users within the higher acuity care market, driving the best possible outcomes for the people we support.

In addition, we anticipate accelerated growth of new service provision and development of high specification environments as Blue Ribbon expands its geographical and commissioner footprint.

Blue Ribbon will continue investing in its people, quality and systems, as well as a focus on building an experienced market leading executive leadership and management team to deliver our strategic plans.

 

Blue Ribbon Healthcare Limited

Director's Report for the Year Ended 31 October 2025

Disclosure of information to the auditors

The director has taken steps that she ought to have taken as a director in order to make herself aware of any relevant audit information and to establish that the company's auditors are aware of that information. The director confirms that there is no relevant information that she knows of and of which she knows the auditors are unaware.

Reappointment of auditors

Hazlewoods LLP have expressed their willingness to continue in office.

Approved by the director on 2 July 2026


C L Smith
Director

 

Blue Ribbon Healthcare Limited

Statement of Director's Responsibilities

The director acknowledges her responsibilities for preparing the Strategic Report, Director's Report and the financial statements in accordance with applicable law and regulations.

Company law requires the director to prepare financial statements for each financial year. Under that law the director has elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the director must not approve the financial statements unless she is satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the director is required to:

select suitable accounting policies and apply them consistently;

make judgements and accounting estimates that are reasonable and prudent;

state whether applicable United Kingdom Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and

prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The director is responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable her to ensure that the financial statements comply with the Companies Act 2006. She is also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

 

Blue Ribbon Healthcare Limited

Independent Auditor's Report to the Members of Blue Ribbon Healthcare Limited

Opinion

We have audited the financial statements of Blue Ribbon Healthcare Limited (the 'company') for the year ended 31 October 2025, which comprise the Profit and Loss Account, Balance Sheet, Statement of Changes in Equity, and Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

give a true and fair view of the state of the company's affairs as at 31 October 2025 and of its profit for the year then ended;

have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and

have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the auditor responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the director's use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the original financial statements were authorised for issue.

Our responsibilities and the responsibilities of the director with respect to going concern are described in the relevant sections of this report.

Other information

The director are responsible for the other information. The other information comprises the information included in the annual report, other than the financial statements and our auditor’s report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

 

Blue Ribbon Healthcare Limited

Independent Auditor's Report to the Members of Blue Ribbon Healthcare Limited

Opinion on other matter prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

the information given in the Strategic Report and Director's Report for the financial year for which the financial statements are prepared is consistent with the financial statements; and

the Strategic Report and Director's Report have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of our knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the Strategic Report and the Director's Report.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or

the financial statements are not in agreement with the accounting records and returns; or

certain disclosures of director's remuneration specified by law are not made; or

we have not received all the information and explanations we require for our audit.

Responsibilities of the director

As explained more fully in the Statement of Director's Responsibilities set out on page 5, the director is responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the director determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the director is responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the director either intends to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditor’s responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Extent to which the audit was capable of detecting irregularities, including fraud

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

We considered the nature of the company’s industry and its control environment and reviewed the company’s documentation of their policies and procedures relating to fraud and compliance with laws and regulations. We also enquired of management about their own identification and assessment of the risks of irregularities.

We obtained an understanding of the legal and regulatory framework that the company operates in and identified the key laws and regulations that had a direct effect on the determination of material amounts and disclosures in the financial statements, including the UK Companies Act and tax legislation, and, those that do not have a direct effect on the financial statements but compliance with which may be fundamental to the company’s ability to operate or to avoid a material penalty.

We discussed among the audit engagement team regarding the opportunities and incentives that may exist within the organisation for fraud and how and where fraud might occur in the financial statements.

 

Blue Ribbon Healthcare Limited

Independent Auditor's Report to the Members of Blue Ribbon Healthcare Limited

In common with all audits conducted in accordance with ISAs (UK), we are also required to perform specific procedures to respond to the risk of management override of controls. In addressing the risk of fraud through management override of controls, we tested the appropriateness of journal entries and other adjustments; assessed whether the judgements made in accounting estimates are indicative of a potential bias; and evaluated the business rationale of any significant transactions that are unusual or outside the normal course of business.

In addition to the above, our procedures to respond to the risks identified included the following:

reviewing financial statement disclosures by testing to supporting documentation to assess compliance with provisions of relevant laws and regulations described as having a direct effect on the financial statements;

performing analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatements due to fraud;

enquiring of management concerning actual and potential litigation and claims and instances of non-compliance with laws and regulations; and

reading minutes of meetings of those charged with governance.

Our audit procedures were designed to respond to risks of material misstatement in the financial statements, recognising that the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery, misrepresentations or through collusion. There are inherent limitations in the audit procedures performed and the further removed non-compliance with laws and regulations is from the events and transactions reflected in the financial statements, the less likely we are to become aware of it.

A further description of our responsibilities is available on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

 

Blue Ribbon Healthcare Limited

Independent Auditor's Report to the Members of Blue Ribbon Healthcare Limited

Use of our report
This report is made solely to the company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company’s members those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company’s members as a body, for our audit work, for this report, or for the opinions we have formed.





Stephanie Hayman (Senior Statutory Auditor)
For and on behalf of Hazlewoods LLP, Statutory Auditor

Windsor House
Bayshill Road
Cheltenham
GL50 3AT

2 July 2026

 

Blue Ribbon Healthcare Limited

Profit and Loss Account for the Year Ended 31 October 2025

Note

2025
£

2024
£

Turnover

3

17,039,738

14,178,999

Cost of sales

 

(11,434,172)

(8,847,188)

Gross profit

 

5,605,566

5,331,811

Administrative expenses

 

(4,120,123)

(3,824,062)

Other operating income

4

508

5,018

Operating profit

5

1,485,951

1,512,767

Other interest receivable and similar income

6

50,727

-

Interest payable and similar expenses

7

(395,864)

(156,757)

   

(345,137)

(156,757)

Profit before tax

 

1,140,814

1,356,010

Tax on profit

11

190,191

(245,374)

Profit for the financial year

 

1,331,005

1,110,636

The above results were derived from continuing operations.

The company has no recognised gains or losses for the year other than the results above.

 

Blue Ribbon Healthcare Limited

(Registration number: 10165316)
Balance Sheet as at 31 October 2025

Note

2025
£

2024
£

Fixed assets

 

Tangible assets

12

1,060,081

960,521

Current assets

 

Debtors

13

5,271,080

1,865,532

Cash at bank and in hand

 

1,360,790

1,276,734

 

6,631,870

3,142,266

Creditors: Amounts falling due within one year

14

(3,881,528)

(1,601,362)

Net current assets

 

2,750,342

1,540,904

Total assets less current liabilities

 

3,810,423

2,501,425

Creditors: Amounts falling due after more than one year

14

-

(8,570)

Provisions for liabilities

11

(51,616)

(65,053)

Net assets

 

3,758,807

2,427,802

Capital and reserves

 

Called up share capital

17

200

200

Share premium reserve

49,900

49,900

Profit and loss account

3,708,707

2,377,702

Shareholders' funds

 

3,758,807

2,427,802

Approved and authorised by the director on 2 July 2026
 


C L Smith
Director

 

Blue Ribbon Healthcare Limited

Statement of Changes in Equity for the Year Ended 31 October 2025

Share capital
£

Share premium
£

Profit and loss account
£

Total
£

At 1 November 2024

200

49,900

2,377,702

2,427,802

Profit for the year

-

-

1,331,005

1,331,005

At 31 October 2025

200

49,900

3,708,707

3,758,807

Share capital
£

Share premium
£

Profit and loss account
£

Total
£

At 1 November 2023

200

49,900

1,267,066

1,317,166

Profit for the year

-

-

1,110,636

1,110,636

At 31 October 2024

200

49,900

2,377,702

2,427,802

 

Blue Ribbon Healthcare Limited

Notes to the Financial Statements for the Year Ended 31 October 2025

 

1

General information

The company is a private company limited by share capital, incorporated in the United Kingdom.

The address of its registered office is:
Gemini House
Blakewater Road
Capricorn Park
Blackburn
BB1 5QR

 

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements were prepared in accordance with Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland and the Companies Act 2006'.

Basis of preparation

These financial statements have been prepared using the historical cost convention except for, where disclosed in these accounting policies, certain items that are shown at fair value.

The presentational currency of the financial statements is Pounds Sterling, being the functional currency of the primary economic environment in which the company operates. Monetary amounts in these financial statements are rounded to the nearest Pound.

Summary of disclosure exemptions

The company has not presented a cash flow statement on the grounds that the company is a wholly owned subsidiary and a group cash flow statement is included in the financial statements of the ultimate parent company.

Name of parent of group

These financial statements are consolidated in the financial statements of Project Bluebell (Topco) Limited.

The financial statements of Project Bluebell (Topco) Limited may be obtained from Companies House.

Going concern

After reviewing the company's forecasts and projections, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. The company therefore continues to adopt the going concern basis in preparing its financial statements.

Judgements and estimation uncertainty

These financial statements do not contain any significant judgements or estimation uncertainty.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the provision of services in the ordinary course of the company’s activities. Turnover is shown net of discounts. The company recognises revenue when the amount of revenue can be reliably measured, it is probable that future economic benefits will flow to the entity and specific criteria have been met for each of the company's activities.

 

Blue Ribbon Healthcare Limited

Notes to the Financial Statements for the Year Ended 31 October 2025

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in the profit and loss account, except that a charge attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Deferred tax is recognised on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements and on unused tax losses or tax credits in the company. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.

The carrying amount of deferred tax assets are reviewed at each reporting date and a valuation allowance is set up against deferred tax assets so that the net carrying amount equals the highest amount that is more likely than not to be recovered based on current or future taxable profit.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Leasehold improvements

20% straight line

Fixtures and fittings

25% straight line

Office equipment

25% straight line

Motor vehicles

20% straight line

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. All trade debtors are repayable within one year and hence are included at the undiscounted cost of cash expected to be received. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the debtors.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and all are repayable within one year and hence are included at the undiscounted amount of cash expected to be paid.

 

Blue Ribbon Healthcare Limited

Notes to the Financial Statements for the Year Ended 31 October 2025

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Leases

Leases in which substantially all the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to profit or loss on a straight-line basis over the period of the lease.

Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessee.

Assets held under finance leases are recognised at the lower of their fair value at inception of the lease and the present value of the minimum lease payments. These assets are depreciated on a straight-line basis over the shorter of the useful life of the asset and the lease term. The corresponding liability to the lessor is included in the Balance Sheet as a finance lease obligation.

Lease payments are apportioned between finance costs in the Profit and Loss Account and reduction of the lease obligation so as to achieve a constant periodic rate of interest on the remaining balance of the liability.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

Financial instruments

Classification
Financial instruments are classified and accounted for according to the substance of the contractual arrangement, as financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities. Where shares are issued, any component that creates a financial liability of the company is presented as a liability on the balance sheet. The corresponding dividends relating to the liability component are charged as interest expenses in the profit and loss account.

 Recognition and measurement
All financial assets and liabilities are initially measured at transaction price (including transaction costs), except for those financial assets classified as at fair value through profit or loss, which are initially measured at fair value (which is normally the transaction price excluding transaction costs), unless the arrangement constitutes a financing transaction. If an arrangement constitutes a financing transaction, the financial asset or financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

 

Blue Ribbon Healthcare Limited

Notes to the Financial Statements for the Year Ended 31 October 2025

Impairment
Assets, other than those measured at fair value, are assessed for indicators of impairment at each balance sheet date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss as described below.

A non financial asset is impaired where there is objective evidence that, as a result of one or more events that occurred after initial recognition, the estimated recoverable value of the asset has been reduced. The recoverable amount of an asset is the higher of its fair value less costs to sell and its value in use.

The recoverable amount of goodwill is derived from measurement of the present value of the future cash flows of the cash-generating units ('CGUs') of which the goodwill is a part. Any impairment loss in respect of a CGU is allocated first to the goodwill attached to that CGU, and then to other assets within that CGU on a pro-rata basis.

Where indicators exist for a decrease in impairment loss, the prior impairment loss is tested to determine reversal. An impairment loss is reversed on an individual impaired asset to the extent that the revised recoverable value does not lead to a revised carrying amount higher than the carrying value had no impairment been recognised. Where a reversal of impairment occurs in respect of a CGU, the reversal is applied first to the assets (other than goodwill) of the CGU on a pro-rata basis and then to any goodwill allocated to that CGU.

For financial assets carried at amortised cost, the amount of an impairment is the difference between the asset’s carrying amount and the present value of estimated future cash flows, discounted at the financial asset’s original effective interest rate.

For financial assets carried at cost less impairment, the impairment loss is the difference between the asset’s carrying amount and the best estimate of the amount that would be received for the asset if it were to be sold at the reporting date.

Where indicators exist for a decrease in impairment loss, and the decrease can be related objectively to an event occurring after the impairment was recognised, the prior impairment loss is tested to determine reversal. An impairment loss is reversed on an individual impaired financial asset to the extent that the revised recoverable value does not lead to a revised carrying amount higher than the carrying value had no impairment been recognised.

 

3

Turnover

The total turnover of the company has been derived from its principal activity wholly undertaken in the United Kingdom.

 

4

Other operating income

The analysis of the company's other operating income for the year is as follows:

2025
£

2024
£

Rental income

508

5,018

 

5

Operating profit

Arrived at after charging

2025
£

2024
£

Depreciation expense

393,287

344,377

Operating lease expense - property

524,532

509,894

Operating lease expense - other

75,321

98,689

 

6

Other interest receivable and similar income

2025
£

2024
£

Interest income on bank deposits

50,727

-

 

Blue Ribbon Healthcare Limited

Notes to the Financial Statements for the Year Ended 31 October 2025

 

7

Interest payable and similar expenses

2025
£

2024
£

Interest on bank overdrafts and borrowings

327,448

72,474

Interest on obligations under finance leases and hire purchase contracts

-

1,783

Interest expense on other finance liabilities

68,416

82,500

395,864

156,757

 

8

Staff costs

The aggregate payroll costs (including director's remuneration) were as follows:

2025
£

2024
£

Wages and salaries

10,461,718

8,089,012

Social security costs

1,167,187

722,594

Pension costs, defined contribution scheme

181,840

124,641

Other employee expense

548,524

331,602

12,359,269

9,267,849

The average number of persons employed by the company (including the director) during the year, analysed by category was as follows:

2025
No.

2024
No.

Care staff

370

278

Administration and support

32

28

402

306

 

Blue Ribbon Healthcare Limited

Notes to the Financial Statements for the Year Ended 31 October 2025

 

9

Director's remuneration

The director's remuneration for the year was as follows:

2025
£

2024
£

Remuneration

150,600

293,102

Contributions paid to money purchase schemes

1,321

2,557

151,921

295,659

 

10

Auditors' remuneration

2025
£

2024
£

Audit of the financial statements

11,460

10,920

 

Blue Ribbon Healthcare Limited

Notes to the Financial Statements for the Year Ended 31 October 2025

 

11

Taxation

Tax charged/(credited) in the profit and loss account

2025
£

2024
£

Current taxation

UK corporation tax

43,084

270,882

UK corporation tax adjustment to prior periods

(219,838)

(5,063)

(176,754)

265,819

Deferred taxation

Arising from origination and reversal of timing differences

(13,437)

(23,374)

Arising from previously unrecognised tax loss, tax credit or temporary difference of prior periods

-

2,929

Total deferred taxation

(13,437)

(20,445)

Tax (receipt)/expense in the income statement

(190,191)

245,374

The tax on profit before tax for the year is lower than the standard rate of corporation tax in the UK (2024 - lower than the standard rate of corporation tax in the UK) of 25% (2024 - 25%).

The differences are reconciled below:

2025
£

2024
£

Profit before tax

1,140,814

1,356,010

Corporation tax at standard rate

285,204

339,003

Decrease in UK and foreign current tax from adjustment for prior periods

(219,838)

(5,063)

Tax increase from effect of capital allowances and depreciation

49,590

27,861

Effect of expense not deductible in determining taxable profit (tax loss)

29,218

43,382

Decrease from tax losses for which no deferred tax asset was recognised

(1,758)

-

Tax decrease arising from group relief

(332,607)

(164,329)

Deferred tax expense from unrecognised temporary difference from a prior period

-

2,929

Tax increase from other tax effects

-

1,591

Total tax (credit)/charge

(190,191)

245,374

 

Blue Ribbon Healthcare Limited

Notes to the Financial Statements for the Year Ended 31 October 2025

Deferred tax

Deferred tax assets and liabilities

2025

Liability
£

Fixed asset timing differences

56,346

Short term timing differences

(4,730)

51,616

2024

Liability
£

Fixed asset timing differences

68,623

Short term timing differences

(3,570)

65,053

 

12

Tangible assets

Leasehold improvements
£

Furniture, fittings and equipment
 £

Motor vehicles
 £

Total
£

Cost

At 1 November 2024

1,226,584

504,851

94,859

1,826,294

Additions

390,447

102,400

-

492,847

At 31 October 2025

1,617,031

607,251

94,859

2,319,141

Depreciation

At 1 November 2024

574,762

255,223

35,788

865,773

Charge for the year

262,492

111,823

18,972

393,287

At 31 October 2025

837,254

367,046

54,760

1,259,060

Carrying amount

At 31 October 2025

779,777

240,205

40,099

1,060,081

At 31 October 2024

651,822

249,628

59,071

960,521


Leased assets
Included within the net book value of tangible fixed assets is £16,473 (2024 - £23,533) in respect of assets held under finance leases and similar hire purchase contracts. Depreciation for the year on these assets was £7,060 (2024 - £10,686).

 

Blue Ribbon Healthcare Limited

Notes to the Financial Statements for the Year Ended 31 October 2025

 

13

Debtors

2025
£

2024
£

Trade debtors

775,149

796,357

Amounts owed by group undertakings

3,407,190

519,213

Other debtors

21,071

7,896

Prepayments

1,067,670

542,066

5,271,080

1,865,532

 

14

Creditors

Note

2025
£

2024
£

Due within one year

 

Loans and borrowings

15

8,571

9,350

Trade creditors

 

251,687

311,094

Amounts due to group undertakings

 

2,235,425

44,423

Social security and other taxes

 

347,333

214,516

Outstanding defined contribution pension costs

 

44,194

33,362

Other creditors

 

223,031

168,753

Accruals

 

737,130

554,156

Corporation tax liability

11

34,157

265,708

 

3,881,528

1,601,362

Due after one year

 

Loans and borrowings

15

-

8,570

 

15

Loans and borrowings

Current loans and borrowings

2025
£

2024
£

Hire purchase contracts

8,571

9,350

Non-current loans and borrowings

2025
£

2024
£

Hire purchase contracts

-

8,570

Hire purchase contracts are secured on the assets to which they relate.

 

Blue Ribbon Healthcare Limited

Notes to the Financial Statements for the Year Ended 31 October 2025

 

16

Pension and other schemes

Defined contribution pension scheme

The company operates a defined contribution pension scheme. The pension cost charge for the year represents contributions payable by the company to the scheme and amounted to £181,840 (2024 - £124,641).

Contributions totalling £44,194 (2024 - £33,362) were payable to the scheme at the end of the year and are included in creditors.

 

17

Share capital

Allotted, called up and fully paid shares

2025

2024

No.

£

No.

£

Ordinary shares of £1 each

200

200

200

200

       
 

18

Obligations under leases and hire purchase contracts

Operating leases

The total of future minimum lease payments is as follows:

2025
£

2024
£

Not later than one year

493,315

481,461

Later than one year and not later than five years

1,493,850

1,296,657

Later than five years

1,639,207

1,464,696

3,626,372

3,242,814

 

19

Contingent liabilities

The company is bound by an intra-group cross guarantee in respect of bank debt with other members of the group headed by Project Bluebell (Holdco) Limited. The amount guaranteed is £16,500,000 (2024 - £6,400,000).

 

20

Related party transactions

Summary of transactions with key management

Key management personnel are considered to be the directors of the company and key management personnel compensation is disclosed in note 9 to the financial statements.

 

21

Parent and ultimate parent undertaking

The company's immediate parent is Blue Ribbon Healthcare Group Limited, incorporated in the United Kingdom.

 The ultimate parent is Project Bluebell (Topco) Limited, incorporated in the United Kingdom.

 The most senior parent entity producing publicly available financial statements is Project Bluebell (Topco) Limited. These financial statements are available upon request from Companies House.

 The ultimate controlling party is Queens Park Equity LLP, a Limited Liability Partnership registered in the United Kingdom which is considered to have no single controlling party.